vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and Gogo Inc. (GOGO). Click either name above to swap in a different company.
Gogo Inc. is the larger business by last-quarter revenue ($230.6M vs $199.9M, roughly 1.2× Apellis Pharmaceuticals, Inc.). Gogo Inc. runs the higher net margin — -4.3% vs -29.5%, a 25.2% gap on every dollar of revenue. On growth, Gogo Inc. posted the faster year-over-year revenue change (67.3% vs -5.9%). Apellis Pharmaceuticals, Inc. produced more free cash flow last quarter ($-14.3M vs $-25.4M). Over the past eight quarters, Gogo Inc.'s revenue compounded faster (48.7% CAGR vs 7.7%).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
Gogo Inc. is an American provider of in-flight broadband Internet service and other connectivity services for business aircraft, headquartered in Broomfield, Colorado. Through its Gogo LLC subsidiary, Gogo previously provided in-flight WiFi to 17 airlines until the Commercial Air business was sold to Intelsat for $400 million in December 2020. According to Gogo, over 2,500 commercial aircraft and 6,600 business aircraft have been equipped with its onboard Wi-Fi services. The company is the de...
APLS vs GOGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $230.6M |
| Net Profit | $-59.0M | $-10.0M |
| Gross Margin | — | — |
| Operating Margin | -25.6% | 6.2% |
| Net Margin | -29.5% | -4.3% |
| Revenue YoY | -5.9% | 67.3% |
| Net Profit YoY | -62.2% | 64.6% |
| EPS (diluted) | $-0.40 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $199.9M | $230.6M | ||
| Q3 25 | $458.6M | $223.6M | ||
| Q2 25 | $178.5M | $226.0M | ||
| Q1 25 | $166.8M | $230.3M | ||
| Q4 24 | $212.5M | $137.8M | ||
| Q3 24 | $196.8M | $100.5M | ||
| Q2 24 | $199.7M | $102.1M | ||
| Q1 24 | $172.3M | $104.3M |
| Q4 25 | $-59.0M | $-10.0M | ||
| Q3 25 | $215.7M | $-1.9M | ||
| Q2 25 | $-42.2M | $12.8M | ||
| Q1 25 | $-92.2M | $12.0M | ||
| Q4 24 | $-36.4M | $-28.2M | ||
| Q3 24 | $-57.4M | $10.6M | ||
| Q2 24 | $-37.7M | $839.0K | ||
| Q1 24 | $-66.4M | $30.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 87.8% | ||
| Q1 25 | — | 87.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -25.6% | 6.2% | ||
| Q3 25 | 48.7% | 12.9% | ||
| Q2 25 | -18.6% | 15.9% | ||
| Q1 25 | -50.0% | 15.3% | ||
| Q4 24 | -12.3% | -17.5% | ||
| Q3 24 | -24.0% | 19.0% | ||
| Q2 24 | -14.7% | 21.2% | ||
| Q1 24 | -36.0% | 33.2% |
| Q4 25 | -29.5% | -4.3% | ||
| Q3 25 | 47.0% | -0.9% | ||
| Q2 25 | -23.6% | 5.7% | ||
| Q1 25 | -55.3% | 5.2% | ||
| Q4 24 | -17.1% | -20.5% | ||
| Q3 24 | -29.2% | 10.6% | ||
| Q2 24 | -18.9% | 0.8% | ||
| Q1 24 | -38.5% | 29.2% |
| Q4 25 | $-0.40 | $-0.08 | ||
| Q3 25 | $1.67 | $-0.01 | ||
| Q2 25 | $-0.33 | $0.09 | ||
| Q1 25 | $-0.74 | $0.09 | ||
| Q4 24 | $-0.30 | $-0.22 | ||
| Q3 24 | $-0.46 | $0.08 | ||
| Q2 24 | $-0.30 | $0.01 | ||
| Q1 24 | $-0.54 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $125.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $370.1M | $101.1M |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $466.2M | $125.2M | ||
| Q3 25 | $479.2M | $133.6M | ||
| Q2 25 | $370.0M | $102.1M | ||
| Q1 25 | $358.4M | $70.3M | ||
| Q4 24 | $411.3M | $41.8M | ||
| Q3 24 | $396.9M | $176.7M | ||
| Q2 24 | $360.1M | $161.6M | ||
| Q1 24 | $325.9M | $152.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $101.1M | ||
| Q3 25 | $401.2M | $107.0M | ||
| Q2 25 | $156.3M | $102.8M | ||
| Q1 25 | $164.2M | $82.9M | ||
| Q4 24 | $228.5M | $69.3M | ||
| Q3 24 | $237.1M | $52.7M | ||
| Q2 24 | $264.3M | $52.0M | ||
| Q1 24 | $266.7M | $62.4M |
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.3B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $810.7M | ||
| Q2 24 | $904.5M | $802.7M | ||
| Q1 24 | $831.9M | $809.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | $8.5M |
| Free Cash FlowOCF − Capex | $-14.3M | $-25.4M |
| FCF MarginFCF / Revenue | -7.1% | -11.0% |
| Capex IntensityCapex / Revenue | 0.1% | 14.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | $65.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.2M | $8.5M | ||
| Q3 25 | $108.5M | $46.8M | ||
| Q2 25 | $4.4M | $36.7M | ||
| Q1 25 | $-53.4M | $32.5M | ||
| Q4 24 | $19.4M | $-38.3M | ||
| Q3 24 | $34.1M | $25.1M | ||
| Q2 24 | $-8.3M | $24.9M | ||
| Q1 24 | $-133.0M | $29.7M |
| Q4 25 | $-14.3M | $-25.4M | ||
| Q3 25 | $108.3M | $27.3M | ||
| Q2 25 | $4.4M | $33.5M | ||
| Q1 25 | $-53.4M | $29.7M | ||
| Q4 24 | $19.3M | $-42.6M | ||
| Q3 24 | — | $20.7M | ||
| Q2 24 | $-8.4M | $21.6M | ||
| Q1 24 | $-133.3M | $28.2M |
| Q4 25 | -7.1% | -11.0% | ||
| Q3 25 | 23.6% | 12.2% | ||
| Q2 25 | 2.5% | 14.8% | ||
| Q1 25 | -32.0% | 12.9% | ||
| Q4 24 | 9.1% | -30.9% | ||
| Q3 24 | — | 20.6% | ||
| Q2 24 | -4.2% | 21.1% | ||
| Q1 24 | -77.3% | 27.0% |
| Q4 25 | 0.1% | 14.7% | ||
| Q3 25 | 0.0% | 8.7% | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 3.1% | ||
| Q3 24 | 0.0% | 4.4% | ||
| Q2 24 | 0.0% | 3.3% | ||
| Q1 24 | 0.2% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 2.87× | ||
| Q1 25 | — | 2.70× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 29.74× | ||
| Q1 24 | — | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GOGO
| Services | $191.9M | 83% |
| Products | $38.7M | 17% |
| Fcc Reimbursement Program | $2.0M | 1% |
